Simulations Plus/$SLP
1D1W1MYTD1Y5YMAX
Capital at risk
About Simulations Plus
Simulations Plus Inc is engaged in the software industry. It develops and produces software for use in pharmaceutical research and education, and provides consulting and contract research services to the pharmaceutical industry. The company's operating segments include Software and services. The company offers software products for pharmaceutical research such as ADMET (Absorption, Distribution, Metabolism, Excretion, and Toxicity). It generates maximum revenue from the software segment. Maximum revenue is earned from USA following EMEA and Asia Pacific.
- Ticker
- $SLP
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 213
- Headquarters
- Research Triangle Park, United States
- Website
- www.simulations-plus.com
Simulations Plus Metrics
BasicAdvanced
$373M
46.16
$0.40
1.31
-
Price and volume
Market cap
$373M
Beta
1.31
52-week high
$21.01
52-week low
$11.09
Average daily volume
178K
Financial strength
Current ratio
5.538
Quick ratio
5.307
Long term debt to equity
0.003
Total debt to equity
0.004
Profitability
EBITDA (TTM)
15.016
Gross margin (TTM)
63.38%
Net profit margin (TTM)
9.88%
Operating margin (TTM)
15.36%
Effective tax rate (TTM)
35.42%
Revenue per employee (TTM)
$390,000
Management effectiveness
Return on assets (TTM)
5.48%
Return on equity (TTM)
6.17%
Valuation
Price to earnings (TTM)
46.156
Price to revenue (TTM)
4.528
Price to book
2.68
Price to tangible book (TTM)
5.51
Price to free cash flow (TTM)
17.155
Free cash flow yield (TTM)
5.83%
Free cash flow per share (TTM)
1.074
Growth
Revenue change (TTM)
2.08%
Earnings per share change (TTM)
-112.67%
3-year revenue growth (CAGR)
13.80%
10-year revenue growth (CAGR)
15.32%
3-year earnings per share growth (CAGR)
-7.17%
10-year earnings per share growth (CAGR)
3.97%
What the Analysts think about Simulations Plus
Analyst ratings (Buy, Hold, Sell) for Simulations Plus stock.
Analyst projections of the future price of Simulations Plus stock.
Bulls say / Bears say
The proposed Altaris acquisition offers $18.50 per share in cash, a 26% premium to SLP’s 60-day volume-weighted average price, providing a defined potential exit value for shareholders. (SEC)
A major regulatory hurdle has been cleared: the Hart-Scott-Rodino waiting period expired on August 13, 2026, reducing U.S. antitrust execution risk ahead of the expected second-half 2026 closing. (SEC)
Recent operations remain profitable and resilient: fiscal Q3 2026 revenue rose 7%, services revenue grew 20%, gross margin expanded to 69%, and GAAP net income returned to $3.6 million. (SEC)
The $18.50-per-share all-cash offer effectively caps SLP’s upside at the merger consideration, while completion would make Simulations Plus privately held and end its Nasdaq listing. (Nasdaq)
Underlying growth has softened: fiscal Q3 2026 software revenue was flat year over year and nine-month software revenue fell 2%; adjusted net income declined to $15.7 million from $18.7 million. (SEC)
The transaction still requires shareholder approval and certain regulatory approval in France, and the company disclosed risks of closing failure, delays, customer disruption, and employee-retention problems. (SEC)
Data summarised monthly by Lightyear AI. Last updated on 14 Sept 2026.
Simulations Plus Financial Performance
Revenues and expenses
Simulations Plus Earnings Performance
Company profitability
Upcoming events
No upcoming events
Simulations Plus News
AllArticlesVideos
Johnson Fistel Investigates Simulations Plus Following Revenue Guidance Cut and Accounting Disclosures
Newsfile Corp2 days ago
Simulations Plus Announces Expiration of Hart-Scott-Rodino Waiting Period for Pending Acquisition by Altaris
Business Wire1 month ago
Simulations Plus Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Simulations Plus, Inc. - SLP
Business Wire2 months ago
Funds containing Simulations Plus
AllUSDEURGBP
Fund name | Fund size | $SLP weighting |
|---|---|---|
iShares Healthcare Innovation$HEAL | $1.4B | 0.03% |
iShares Healthcare Innovation€2B78 | €1.2B | 0.03% |
iShares Healthcare Innovation£DRDR | £1B | 0.03% |
SPDR Russell 2000 US Small Cap€R2US | €4.8B | 0.01% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.